Notice2021-21655
Foreign-Trade Zone (FTZ) 7-Mayaguez, Puerto Rico, Notification of Proposed Production Activity, AbbVie Ltd. (Pharmaceutical Products), Barceloneta, Puerto Rico
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
October 5, 2021
Issuing agencies
Commerce DepartmentForeign-Trade Zones Board
Full Text
<html>
<head>
<title>Federal Register, Volume 86 Issue 190 (Tuesday, October 5, 2021)</title>
</head>
<body><pre>
[Federal Register Volume 86, Number 190 (Tuesday, October 5, 2021)]
[Notices]
[Page 54923]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2021-21655]
-----------------------------------------------------------------------
DEPARTMENT OF COMMERCE
Foreign-Trade Zones Board
[B-67-2021]
Foreign-Trade Zone (FTZ) 7--Mayaguez, Puerto Rico, Notification
of Proposed Production Activity, AbbVie Ltd. (Pharmaceutical Products),
Barceloneta, Puerto Rico
AbbVie Ltd. (AbbVie) submitted a notification of proposed
production activity to the FTZ Board (the Board) for its facility in
Barceloneta, Puerto Rico within Subzone 7I. The notification conforming
to the requirements of the Board's regulations (15 CFR 400.22) was
received on September 24, 2021.
Pursuant to 15 CFR 400.14(b), FTZ production activity would be
limited to the specific foreign-status materials and specific finished
products described in the submitted notification (summarized below) and
subsequently authorized by the Board. The benefits that may stem from
conducting production activity under FTZ procedures are explained in
the background section of the Board's website--accessible via
<a href="http://www.trade.gov/ftz">www.trade.gov/ftz</a>. The proposed finished products and materials would
be added to the production authority that the Board previously approved
for the operation, as reflected on the Board's website.
The proposed finished products include UBRELVY[supreg] tablets,
ATOGEPANT[supreg] tablets and atogepant and ubrelvy extrudates (duty-
free).
The proposed foreign-status materials include ubrogepant and
atogepant active pharmaceutical ingredients (duty rate 6.5%). The
request indicates both materials are subject to duties under section
301 of the Trade Act of 1974 (section 301), depending on the country of
origin. The applicable Section 301 decisions require subject
merchandise to be admitted to FTZs in privileged foreign status (19 CFR
146.41).
Public comment is invited from interested parties. Submissions
shall be addressed to the Board's Executive Secretary and sent to:
<a href="/cdn-cgi/l/email-protection#294f5d53695d5b484d4c074e465f"><span class="__cf_email__" data-cfemail="ff998b85bf8b8d9e9b9ad1989089">[email protected]</span></a>. The closing period for their receipt is November 15,
2021.
A copy of the notification will be available for public inspection
in the ``Online FTZ Information System'' section of the Board's
website.
For further information, contact Christopher Wedderburn at
<a href="/cdn-cgi/l/email-protection#3172594358421f6654555554435344435f7145435055541f565e47"><span class="__cf_email__" data-cfemail="8dcee5ffe4fea3dae8e9e9e8ffeff8ffe3cdf9ffece9e8a3eae2fb">[email protected]</span></a>.
Dated: September 30, 2021.
Andrew McGilvray,
Executive Secretary.
[FR Doc. 2021-21655 Filed 10-4-21; 8:45 am]
BILLING CODE 3510-DS-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on October 5, 2021.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.